![]() | |
Clinical data | |
---|---|
Trade names | Mavyret, Maviret (combination with glecaprevir) |
Other names | ABT-530 |
Pharmacokinetic data | |
Protein binding | >99.9% |
Elimination half-life | 13 hours |
Excretion | 96.6% in faeces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C57H65F5N10O8 |
Molar mass | 1113.201 g·mol−1 |
3D model (JSmol) | |
| |
|
Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.[citation needed]
References
- ^ Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al. (May 2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMC 5404558. PMID 28193664.
- ^ Johnson LA (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
- ^ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17.